Headquartered in New Haven, CT Fiscal year ends December NYSE: BHVN biohaven.com
Biohaven Ltd. is a clinical-stage biopharmaceutical company with no product revenue. It discovers and develops therapies in immunology, obesity, neuroscience and oncology, and increasingly funds itself through regional and global licensing deals rather than equity.
Its proprietary platforms include:
- **MoDE and TRAP extracellular protein degraders:** BHV-1300, a pan-IgG degrader in Phase 3 for Graves' disease, and BHV-1400, a Gd-IgA1 degrader heading into a pivotal trial in IgA nephropathy. The MoDE IgG portfolio is licensed to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN.
- **Kv7 ion channel platform:** led by the epilepsy candidate opakalim (BHV-7000), being licensed worldwide to SK Biopharmaceuticals.
- **Myostatin-activin pathway inhibition:** taldefgrobep alfa, in Phase 2 for obesity and body recomposition.
The most advanced asset is Vyglxia (troriluzole) for spinocerebellar ataxia. Its resubmitted NDA is under FDA review, with a 1Q 2027 goal date.
Other programs:
- BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor in a Phase 2/3 Parkinson's disease study.
- BHV-8100, a PKM2 modulator in first-in-human testing.
- Intranasal oxytocin for tinnitus.
- Oncology antibody-drug conjugates: BHV-1530 (FGFR3-directed) and BHV-1510 (TROP2-directed), each with a Regeneron clinical supply agreement for Libtayo combinations.
The company also uses AI-enabled tools, including Bexorg's NeuroLens platform, for neuroscience candidate selection. Updated
It’s always a good idea to pay close attention to analyst upgrades. Often, they’re influenced by (1) company fundamentals, such as financial health, future growth, and even meetings with management; (2) industry…
Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of…
Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the…
Pre-Market Stock Futures: The futures are trading modestly higher as Thanksgiving Eve has finally arrived. After a slow start on Tuesday, all the major indices began to rally by noon and finished…
Carl Icahn has made another huge bet, boosting his stake in a utility infrastructure company. It was not the only big insider buying though.
Initial public offerings and a secondary offering inspired insiders to pick up some shares of these biotech companies and others.
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Biohaven, Edwards Lifesciences, Enphase Energy, Halliburton, Invesco, Liberty Energy, Mattel, Netflix, Permian Resources, Range Resources, Roblox, Synchrony Financial and Visa.
Wednesday’s additional top analyst upgrades and downgrades were on Ally Financial, Baker Hughes, Biohaven, Biogen, Bumble, Canopy Growth, Corning, Discover Financial Services, Match, Roku and more.
Friday's additional top analyst upgrades and downgrades were on Applied Materials, Dick’s Sporting Goods, Foot Locker, HP, Meta Platforms, Occidental Petroleum and more.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Biohaven Pharmaceutical, SmileDirectClub, Squarespace and Victoria’s Secret.
Biohaven Ltd. is a clinical-stage biopharmaceutical company with no product revenue. It discovers and develops therapies in immunology, obesity, neuroscience and oncology, and increasingly funds itself through regional and global licensing deals rather than equity.
24/7 Wall St.'s 12-month price target for BHVN is $27.06, rated Buy. The Wall Street consensus target is $23.33. BHVN price prediction →
